×
About 4,772 results

ALLMedicine™ Granulomatosis With Polyangiitis Center

Research & Reviews  2,275 results

Gastrointestinal symptoms as first remarkable signs of ANCA-associated granulomatosis w...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028736
BMC Gastroenterology; Ledó N, Pethő ÁG

Apr 9th, 2021 - Systemic vasculitis associated with antineutrophil cytoplasmic autoantibodies (ANCA) have an extremely wide variety of symptoms, therefore the fast and proper diagnosis is difficult to establish even for experienced physicians. Gastrointestinal ma...

Clinical features of central nervous system involvement in patients with eosinophilic g...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010942
Orphanet Journal of Rare Diseases; Liu S, Guo L et. al.

Apr 1st, 2021 - Central nervous system (CNS) involvement is extremely rare in eosinophilic granulomatosis with polyangiitis (EGPA), but is associated with a poor prognosis in the five-factor score. This study aims to elucidate the clinical features and independen...

Pulmonary Involvement in Primary Systemic Vasculitides.
https://doi.org/10.1093/rheumatology/keab325
Rheumatology (Oxford, England); Makhzoum JP, Grayson PC et. al.

Mar 31st, 2021 - This study describes the spectrum and initial impact of pulmonary manifestations in the primary systemic vasculitides. Description and comparison of pulmonary manifestations in adults with Takayasu's arteritis (TAK), giant cell arteritis (GCA), gr...

Granulomatosis with polyangiitis manifesting as fever of unknown origin.
https://doi.org/10.1136/bcr-2020-239713
BMJ Case Reports; Mahfooz F, Duffee D et. al.

Mar 27th, 2021 - Fever of unknown origin (FUO) has a broad differential diagnosis, including infectious, inflammatory and malignant aetiologies. Granulomatosis with polyangiitis (GPA) can present with non-specific symptoms, including fever, lethargy and flu-like i...

Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with ...
https://doi.org/10.1016/j.jneuroim.2021.577551
Journal of Neuroimmunology; Son H, Lee WJ et. al.

Mar 27th, 2021 - Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis disease involving small-sized vessels. The literature has reported involvement of the central nervous system (CNS) in 5% cases, and isolated CNS involvement is extremely...

see more →

Guidelines  1 results

FDA Approves Pfizer’s Biosimilar, Ruxience™ (Rituximab-pvvr), For Certain Cancers And Autoimmune Conditions
https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_ruxience_rituximab_pvvr_for_certain_cancers_and_autoimmune_conditions

Jul 22nd, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE™ (rituximab-pvvr), a biosimilar to Rituxan® (rituximab),1 for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  2,369 results

Gastrointestinal symptoms as first remarkable signs of ANCA-associated granulomatosis w...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028736
BMC Gastroenterology; Ledó N, Pethő ÁG

Apr 9th, 2021 - Systemic vasculitis associated with antineutrophil cytoplasmic autoantibodies (ANCA) have an extremely wide variety of symptoms, therefore the fast and proper diagnosis is difficult to establish even for experienced physicians. Gastrointestinal ma...

Clinical features of central nervous system involvement in patients with eosinophilic g...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010942
Orphanet Journal of Rare Diseases; Liu S, Guo L et. al.

Apr 1st, 2021 - Central nervous system (CNS) involvement is extremely rare in eosinophilic granulomatosis with polyangiitis (EGPA), but is associated with a poor prognosis in the five-factor score. This study aims to elucidate the clinical features and independen...

Pulmonary Involvement in Primary Systemic Vasculitides.
https://doi.org/10.1093/rheumatology/keab325
Rheumatology (Oxford, England); Makhzoum JP, Grayson PC et. al.

Mar 31st, 2021 - This study describes the spectrum and initial impact of pulmonary manifestations in the primary systemic vasculitides. Description and comparison of pulmonary manifestations in adults with Takayasu's arteritis (TAK), giant cell arteritis (GCA), gr...

Granulomatosis with polyangiitis manifesting as fever of unknown origin.
https://doi.org/10.1136/bcr-2020-239713
BMJ Case Reports; Mahfooz F, Duffee D et. al.

Mar 27th, 2021 - Fever of unknown origin (FUO) has a broad differential diagnosis, including infectious, inflammatory and malignant aetiologies. Granulomatosis with polyangiitis (GPA) can present with non-specific symptoms, including fever, lethargy and flu-like i...

Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with ...
https://doi.org/10.1016/j.jneuroim.2021.577551
Journal of Neuroimmunology; Son H, Lee WJ et. al.

Mar 27th, 2021 - Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis disease involving small-sized vessels. The literature has reported involvement of the central nervous system (CNS) in 5% cases, and isolated CNS involvement is extremely...

see more →

News  115 results

FDA approves rituximab to treat children with rare vasculitis
https://www.mdedge.com/pediatrics/article/209075/pediatrics/fda-approves-rituximab-treat-children-rare-vasculitis?channel=39313
Mark Lesney

Sep 30th, 2019 - The Food and Drug Administration approved rituximab (Rituxan) by injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoid treatment, accord.

FDA OKs First Treatment for Rare Types of Vasculitis in Kids
https://www.medscape.com/viewarticle/919198

Sep 29th, 2019 - The US Food and Drug Administration (FDA) has approved rituximab (Rituxan, Genentech) injection, in combination with glucocorticoids, to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children aged 2 years or ol...

FDA approves rituximab biosimilar for cancer, autoimmune disorders
https://www.mdedge.com/hematology-oncology/article/205220/b-cell-lymphoma/fda-approves-rituximab-biosimilar-cancer?channel=59374
Christopher Palmer

Jul 23rd, 2019 - The Food and Drug Administration has approved rituximab-pvvr (Ruxience) for adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis and microscopic polyangiitis. It is the first biosimilar approve.

FDA Approves Pfizer’s Biosimilar, Ruxience™ (Rituximab-pvvr), For Certain Cancers And Autoimmune Conditions
https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_ruxience_rituximab_pvvr_for_certain_cancers_and_autoimmune_conditions

Jul 22nd, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE™ (rituximab-pvvr), a biosimilar to Rituxan® (rituximab),1 for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL...

Vasculitis: Osmosis Study Video
https://www.medscape.com/viewarticle/907189

Jan 17th, 2019 - What is vasculitis? Vasculitis is an inflammation of the blood vessels that typically has some immune system-related cause. This video covers the pathophysiology of vasculitis in general, as well as more specific conditions like giant cell arterit...

see more →

Patient Education  9 results see all →